JP3683533B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP3683533B2 JP3683533B2 JP2002003652A JP2002003652A JP3683533B2 JP 3683533 B2 JP3683533 B2 JP 3683533B2 JP 2002003652 A JP2002003652 A JP 2002003652A JP 2002003652 A JP2002003652 A JP 2002003652A JP 3683533 B2 JP3683533 B2 JP 3683533B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- test
- ultraviolet absorber
- octyl methoxycinnamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は皮膚外用剤に関する。
また、本発明は、紫外線吸収剤のオクチルメトキシシンナメートの刺激を緩和した皮膚外用剤に関する。
【0002】
【従来の技術】
紫外線吸収剤は、種々の化粧料に配合されている。
その目的は、紫外線による製品の分解防止と、皮膚の損傷(日焼け止め)に大別される。
【0003】
化粧料中の紫外線吸収剤は、敏感肌の使用者が刺激を感じる場合がある。
そのため、その刺激を緩和する方法が強く求められていた。
【0004】
【発明が解決しようとする課題】
本発明者らは、化粧料基剤に適した多くの汎用原料を探索した結果、ポリプロピレングリコールジメチルエーテルが、紫外線吸収剤のオクチルメトキシシンナメートの経皮吸収抑制効果が極めて高いことを発見した。
【0005】
そして、前記ポリプロピレングリコールジメチルエーテルを皮膚外用剤に配合すると、紫外線吸収剤のオクチルメトキシシンナメートの効果を損なうことなく、皮膚刺激を緩和できることを見出した。
【0006】
さらに、ポリプロピレングリコールジメチルエーテルは紫外線吸収剤のオクチルメトキシシンナメートの感作性を抑制する効果があることを発見した。
【0007】
特に、日焼け止め化粧料には一定量以上の紫外線吸収剤のオクチルメトキシシンナメートが配合されるため、本発明の意義が大きい。
【0008】
【課題を解決するための手段】
本発明は下記の通りである。
【0009】
1.ポリプロピレングリコールジメチルエーテルを含有する皮膚外用剤。
2.紫外線吸収剤のオクチルメトキシシンナメートと、ポリプロピレングリコールジメチルエーテルとを含有する皮膚外用剤。
3.前記皮膚外用剤が日焼け止め化粧料である上記の皮膚外用剤。
【0010】
【発明の実施の形態】
以下、本発明を説明する。
【0011】
本発明に用いるポリプロピレングリコールジメチルエーテル(DMPPGという)は、下記の構造式(1)を有する公知の化合物である。
【化1】
(nは整数)
分子量は任意であり、例えば、数平均分子量が1000のDMPPG(DMPPG1000という)、数平均分子量が2000のDMPPG(DMPPG2000という)などを使用できる。
DMPPGは、公知の製造方法により任意の数平均分子量に調整し使用することができる。
数平均分子量1000〜2000のものが好ましい。
数平均分子量は化粧品原料基準 第二版注解I(1984年 薬事日報社)の942頁に記載された方法で求めることが出来る。
【0012】
ポリプロピレングリコールジメチルエーテルは、皮膚外用剤に対して0.1〜20.0質量%(好ましくは、1.0〜10.0質量%)配合される。
例えば、紫外線吸収剤のオクチルメトキシシンナメートの刺激緩和剤若しくは経皮吸収抑制剤として、紫外線吸収剤のオクチルメトキシシンナメートの配合量に応じて、実際の配合量が適宜決定される。
【0013】
本発明に用いる紫外線吸収剤例はオクチルメトキシシンナメート(商品名:パルソール MCX )である。
【0014】
紫外線吸収剤のオクチルメトキシシンナメートの配合量は、皮膚外用剤の分解安定性に使用する場合は、皮膚外用剤全量に対して、通常、0.01〜1.0質量%である。
紫外線吸収剤のオクチルメトキシシンナメートを、紫外線から皮膚を保護する場合に使用する場合は、皮膚外用剤全量に対して、通常、1.0〜5.0質量%である。
特に、日焼け止め化粧料として使用する場合は、通常、5.0〜15.0質量%である。
紫外線吸収剤のオクチルメトキシシンナメートを5.0質量%以上配合した場合は、敏感肌に対する皮膚刺激を感じる割合が高くなるので、刺激緩和の効果が大きくなる。
【0015】
本発明は、特にオクチルメトキシシンナメート(商品名:パルソールMCX)の刺激緩和効果が高い。
ポリプロピレングリコールはオクチルメトキシシンナメートに対して、10〜50質量%の割合で配合することが好ましく、例えば、メトキシシンナメート7.5質量%に対して、ポリプロピレングリコールジメチルエーテルを2〜4質量%で配合した場合に、オクチルメトキシシンナメートの経皮吸収抑制効果が高い。
【0016】
皮膚外用剤の剤形は限定されない。
例えば、液状、乳液状、ゲル状、ペースト状、クリーム状がある。
日焼け止め化粧料の製品形態も制限されない。日焼け止め化粧料とは紫外線から皮膚を保護する化粧料を意味する。
本発明の皮膚外用剤は、上記必須成分を、皮膚外用剤の製剤成分(例えば、保湿剤、油分、界面活性剤、増粘剤、金属封鎖剤、紫外線防止剤、薬剤、色素、香料)に配合し、目的の剤形に応じて、常法により製造される。
【0017】
【実施例】
次に実施例により本発明を具体的に説明する。配合量は質量%を表わす。
【0018】
各化粧料について、下記の試験を行って、本発明の効果を確認した。
【0019】
「経皮吸収試験」
試験方法:
1.市販のラボスキン(ヘアレスマウス)をフランツ型拡散セルに装着する。
2.拡散セルのドナー側に、脂溶性薬剤を配合した被験液を注入する。
3.拡散セルのレシーバー側に、0.1%アジ化ナトリウム、0.5〜6%ポリオキシエチレン(20)オレイルエーテルを加えたりん酸緩衝液(pH 7.4)を注入する。
4.レシーバー側をマグネティックスターラーで撹拌しながら、恒温層で37℃に保つ。
5.経時的にレシーバー側よりサンプリングを行う。
6.HPLCにより被験物質の定量を行う。
評価方法:
レシーバー側へ透過した被験物質の累積透過量により、経皮吸収性を判定する。
【0020】
「連続皮膚刺激試験」
試験方法:
1.脂溶性薬剤を配合した被験液0.05mlをモルモットの背部2×2cmに塗布(1回目塗布)する。
2.24時間後に2回目の塗布を行う。
3.さらに24時間後に3回目の塗布を行う。
評価方法:
2回目及び3回目の塗布前及び3回目塗布後24時間後に、紅斑、浮腫等の皮膚反応を肉眼で観察する。評価は以下の基準で行い、3回の評点の平均値を皮膚反応スコアとする。
皮膚反応の評価基準
皮膚反応の程度 評点
紅斑が全く認められないもの 0
わずかな紅斑が認められるもの 1
明らかな紅斑がみとめられるもの 2
強紅斑あるいはわずかな浮腫、痂皮がみとめられるもの 3
明らかな浮腫、痂皮が認められるもの 4
【0021】
1.紫外線吸収剤とポリプロピレングリコールジメチルエーテル(DMPPG)とを含有する化粧料
「実施例1〜2」
下記表1の処方のサンスクリーンを常法により製造した。
経皮吸収試験及び連続皮膚刺激試験を行った。結果を図1及び図2に示す。
ポリプロピレングリコールジメチルエーテルは、数平均分子量が2000のDMPPG2000、数平均分子量が1000のDMPPG1000を使用した。
紫外線吸収剤はオクチルメトキシシンナメート(MCXという)を使用した。
【0022】
【表1】
【0023】
「図1の説明」
実施例1及び2の化粧料は、比較例1(対照)よりも、24時間累積透過量が小さく、経皮吸収抑制効果を有することが確認できる。
【0024】
「図2の説明」
実施例1及び2の化粧料は、比較例1(対照)よりも、皮膚刺激が小さいことが確認できる。
【0025】
「感作抑制試験」
次に、実施例2(紫外線吸収剤とDMPPGとを配合)、比較例1(紫外線吸収剤を配合し、DMPPGを配合しない)、比較例2(紫外線吸収剤もDMPPGも配合しない)の化粧料について、下記のMaximization Test(MAX法)により、紫外線吸収剤の感作抑制効果を調べた。
結果を「表2」に示す。
この結果から、ポリプロピレングリコールジメチルエーテルは紫外線吸収剤に対して優れた感作抑制効果があることが分かる。
【0026】
「MAX法」(モルモット皮膚接触感作性試験)
7〜10週齢の健常なハートレイ系モルモット1群5匹を使用し、MagnussonおよびKligmanのGPMT法(guinea pig maximization test, 1970 Allergic contact dermatitis in the guinea pig. Springfield. Illinois. C.C.Thomas)に準じて行った。
感作処置は、下記▲1▼〜▲3▼の順に、モルモットの肩口左右2例、合計6ヶ所に皮内注射する。
▲1▼ 0.1mLフロインド完全アジュバンド(Freund's complete adjuvant:以下、FCAと略す。Difco社製)の水乳化液(FCA:H2O=1:1,V/V)、
▲2▼ 0.1mL被験物質溶液(5、7.5% MCX流動パラフィン溶液)
▲3▼ ▲2▼の倍濃度のMCX流動パラフィン溶液とFCAの混合物、
7日後、前日剃毛後10 W/V %ラウリル硫酸ソーダ/白色ワセリンを少量塗布しておいた注射部位に、被験物質溶液(5、7.5% MCX流動パラフィン溶液)0.2mLを48時間閉塞下に塗布し、感作処置を終了した。
誘発試験は、上記操作終了後2週間目に、被験液10μl(表2記載の被験液)を、剃毛した背部および腹部皮膚に24時間開放下に塗布して行った。
各試験に際しては、対照としてFCAの水乳化物のみを皮内注射しておいた同数の動物を同時使用し、非特異的皮膚刺激性反応を区別した。
判定は、塗布後48時間目に、以下の判定基準に従って行った。
感作率、評価点は、下記により求めた。
感作率=皮膚反応を呈した動物数/感作処置した動物数
評価点=Σ(紅斑の評点+浮腫の評点)/感作処置した動物数
【0027】
【表2】
【0028】
以下に、本発明の実施例を挙げる。
いずれも、紫外線吸収剤の経皮吸収が抑制され、刺激緩和効果を有する。
【0029】
実施例3 サンスクリーン
オクチルメトキシシンナメート 7.5
DMPPG1000 2.0
t−ブチルメトキシジベンゾイルメタン 0.1
二酸化チタン 5.0
デカメチルシクロペンタシロキサン 30.0
POE・メチルポリシロキサン共重合体 3.0
有機変性モンモリロナイト 0.8
1,3−ブチレングリコール 5.0
アルブチン 5.0
防腐剤 適量
香料 適量
精製水 残余
【0030】
実施例4 クリーム
(製法)Aの成分を加熱融解し、Bを攪拌しながら加える。ホモミキサーで処理し、乳化粒子を細かくした後、攪拌しながら急冷し、クリームを得る。
【0031】
実施例5 化粧水
(製法)Bを調整する。別にエタノールにAのほかの成分を溶解してAを調整し、これをBに加えて可溶化し、ろ過して化粧水を得る。
【0032】
実施例6 乳液
(製法)Bを調整し、70℃に保つ。Aの成分を混合し、加熱融解して70℃に保つ。BにAを加えてホモミキサーで均一に乳化、攪拌しながら急冷し、乳液を得る。
【0033】
実施例7 日焼け止めヘアージェル
(製法)AをBに攪拌溶解し、Cを加えた後、分散機にて分散する。これにDを加え、攪拌し、目的のヘアージェルを得る。
【0034】
実施例8 日焼け止め乳化ファンデーション
(製法)Aを攪拌後、十分に混合粉砕されたBを添加し、ホモミキサー処理する。Cを溶解後これに加えホモミキサー処理し、日焼け止め乳化ファンデーションを得る。
【0035】
【発明の効果】
1)本発明の皮膚外用剤は、紫外線吸収剤のオクチルメトキシシンナメートの経皮吸収抑制効果に優れている。
2)本発明の皮膚外用剤は、紫外線吸収剤のオクチルメトキシシンナメートの皮膚刺激緩和効果に優れている。
3)本発明の皮膚外用剤は、紫外線吸収剤のオクチルメトキシシンナメートの感作抑制効果に優れている。
4)本発明の皮膚外用剤は、紫外線吸収剤のオクチルメトキシシンナメートが経皮に吸収されないので、紫外線防止効果と安全性に優れている。
【図面の簡単な説明】
【図1】 紫外線吸収剤のオクチルメトキシシンナメートの24時間累積透過量を示すグラフである。
【図2】 紫外線吸収剤のオクチルメトキシシンナメートの連続皮膚刺激試験結果を示すグラフである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an external preparation for skin.
Moreover, this invention relates to the skin external preparation which relieve | moderated irritation | stimulation of octyl methoxycinnamate of an ultraviolet absorber.
[0002]
[Prior art]
Ultraviolet absorbers are blended in various cosmetics.
The purpose is roughly divided into prevention of product decomposition by ultraviolet rays and skin damage (sunscreen).
[0003]
Ultraviolet absorbers in cosmetics may cause irritation to users of sensitive skin.
Therefore, there has been a strong demand for a method for alleviating the stimulus.
[0004]
[Problems to be solved by the invention]
As a result of searching for many general-purpose raw materials suitable for cosmetic bases, the present inventors have found that polypropylene glycol dimethyl ether has a very high transdermal absorption-inhibiting effect of octylmethoxycinnamate , an ultraviolet absorber.
[0005]
And when the said polypropylene glycol dimethyl ether was mix | blended with the skin external preparation, it discovered that skin irritation could be relieved, without impairing the effect of the octyl methoxycinnamate of a ultraviolet absorber.
[0006]
Furthermore, it discovered that polypropylene glycol dimethyl ether had the effect which suppresses the sensitization property of the ultraviolet absorber octyl methoxycinnamate .
[0007]
In particular, since the sunscreen cosmetic contains a certain amount or more of the ultraviolet absorber octyl methoxycinnamate , the significance of the present invention is great.
[0008]
[Means for Solving the Problems]
The present invention is as follows.
[0009]
1. A skin external preparation containing polypropylene glycol dimethyl ether.
2. A skin external preparation containing octyl methoxycinnamate as an ultraviolet absorber and polypropylene glycol dimethyl ether.
3. Said skin external preparation whose said external skin preparation is sunscreen cosmetics.
[0010]
DETAILED DESCRIPTION OF THE INVENTION
The present invention will be described below.
[0011]
Polypropylene glycol dimethyl ether (referred to as DMPPG) used in the present invention is a known compound having the following structural formula (1).
[Chemical 1]
(N is an integer)
The molecular weight is arbitrary, and for example, DMPPG having a number average molecular weight of 1000 (referred to as DMPPG1000), DMPPG having a number average molecular weight of 2000 (referred to as DMPPG2000), and the like can be used.
DMPPG can be used after adjusting to an arbitrary number average molecular weight by a known production method.
Those having a number average molecular weight of 1000 to 2000 are preferred.
The number average molecular weight can be determined by the method described on page 942 of Cosmetic Raw Material Standards Second Edition Comment I (1984 Yakuji Nippo).
[0012]
Polypropylene glycol dimethyl ether is blended in an amount of 0.1 to 20.0% by mass (preferably 1.0 to 10.0% by mass) with respect to the external preparation for skin.
For example, the irritation reducing agents or percutaneous absorption inhibitor octyl methoxycinnamate UV absorbers, depending on the amount of octyl methoxycinnamate UV absorbers, the amount actually incorporated is determined appropriately.
[0013]
An example of the ultraviolet absorber used in the present invention is octyl methoxycinnamate (trade name: Pulsol MCX ).
[0014]
The blending amount of the octyl methoxycinnamate as the ultraviolet absorber is usually 0.01 to 1.0% by mass based on the total amount of the external preparation for skin when used for the decomposition stability of the external preparation for skin.
When using the ultraviolet absorbent octyl methoxycinnamate to protect the skin from ultraviolet rays, it is usually 1.0 to 5.0% by mass relative to the total amount of the external preparation for skin.
In particular, when used as a sunscreen cosmetic, it is usually 5.0 to 15.0% by mass.
When blending 5.0% by mass or more of octyl methoxycinnamate, which is an ultraviolet absorber, the ratio of feeling skin irritation to sensitive skin increases, so that the effect of mitigating irritation increases.
[0015]
In particular, the present invention has a high stimulus mitigation effect of octyl methoxycinnamate (trade name: Pulsol MCX).
Polypropylene glycol is preferably blended at a ratio of 10 to 50% by mass with respect to octyl methoxycinnamate. For example, polypropylene glycol dimethyl ether is blended at 2 to 4% by mass with respect to 7.5% by mass of methoxycinnamate. In this case, the effect of octylmethoxycinnamate on percutaneous absorption is high.
[0016]
The dosage form of the external preparation for skin is not limited.
For example, there are liquid, emulsion, gel, paste, and cream.
The product form of sunscreen cosmetics is not limited. Sunscreen cosmetics mean cosmetics that protect the skin from ultraviolet rays.
In the external preparation for skin of the present invention, the essential components described above are used as preparation ingredients for external preparations for skin (for example, humectants, oils, surfactants, thickeners, sequestering agents, UV protection agents, drugs, pigments, and fragrances). It is blended and manufactured by a conventional method according to the target dosage form.
[0017]
【Example】
Next, the present invention will be described specifically by way of examples. A compounding quantity represents the mass%.
[0018]
Each cosmetic was subjected to the following test to confirm the effect of the present invention.
[0019]
"Percutaneous absorption test"
Test method:
1. A commercially available lab skin (hairless mouse) is attached to the Franz diffusion cell.
2. A test solution containing a fat-soluble drug is injected into the donor side of the diffusion cell.
3. A phosphate buffer solution (pH 7.4) containing 0.1% sodium azide and 0.5-6% polyoxyethylene (20) oleyl ether is injected into the receiver side of the diffusion cell.
4). While stirring the receiver side with a magnetic stirrer, keep it at 37 ° C in a constant temperature layer.
5. Sampling from the receiver side over time.
6). Quantify the test substance by HPLC.
Evaluation methods:
The percutaneous absorbability is determined based on the cumulative permeation amount of the test substance permeated to the receiver side.
[0020]
"Continuous skin irritation test"
Test method:
1. 0.05 ml of a test solution containing a fat-soluble drug is applied to the back 2 × 2 cm of the guinea pig (first application).
2. After 24 hours, apply a second time.
3. After a further 24 hours, a third application is performed.
Evaluation methods:
Skin reactions such as erythema and edema are observed with the naked eye before the second and third application and 24 hours after the third application. Evaluation is performed according to the following criteria, and the average value of the three scores is taken as the skin reaction score.
Evaluation criteria for skin reaction Degree of skin reaction Grade No erythema observed 0
Slight erythema is observed 1
Obvious erythema 2
Sick erythema or slight edema, crusts 3
Obvious edema and crusts 4
[0021]
1. Cosmetics “Examples 1-2” containing an ultraviolet absorber and polypropylene glycol dimethyl ether (DMPPG)
Sunscreens having the formulations shown in Table 1 below were produced by a conventional method.
A percutaneous absorption test and a continuous skin irritation test were performed. The results are shown in FIGS.
As the polypropylene glycol dimethyl ether, DMPPG2000 having a number average molecular weight of 2000 and DMPPG1000 having a number average molecular weight of 1000 were used.
As the ultraviolet absorber, octyl methoxycinnamate (referred to as MCX) was used.
[0022]
[Table 1]
[0023]
"Explanation of Figure 1"
It can be confirmed that the cosmetics of Examples 1 and 2 have a 24-hour cumulative permeation amount smaller than that of Comparative Example 1 (control) and have a transdermal absorption suppressing effect.
[0024]
"Explanation of Figure 2"
It can be confirmed that the cosmetics of Examples 1 and 2 have less skin irritation than Comparative Example 1 (control).
[0025]
"Sensitivity suppression test"
Next, cosmetics of Example 2 (blending ultraviolet absorber and DMPPG), Comparative Example 1 (blending ultraviolet absorber and not DMPPG), Comparative Example 2 (blending neither UV absorber nor DMPPG) The sensitization inhibitory effect of the ultraviolet absorber was examined by the following Maximization Test (MAX method).
The results are shown in “Table 2”.
From this result, it can be seen that polypropylene glycol dimethyl ether has an excellent sensitization-inhibiting effect with respect to ultraviolet absorbers.
[0026]
"MAX method" (guinea pig skin contact sensitization test)
5 groups of 7 to 10-week-old healthy Hartley guinea pigs were used according to Magnusson and Kligman's GPMT method (guinea pig maximization test, 1970 Allergic contact dermatitis in the guinea pig. Springfield. Illinois. CCThomas) It was.
The sensitization treatment is carried out intradermally in 6 cases, 2 cases on the left and right sides of the shoulder of the guinea pig in the order of (1) to (3) below.
(1) 0.1 mL Freund's complete adjuvant (Freund's complete adjuvant: hereinafter abbreviated as FCA, manufactured by Difco) water emulsion (FCA: H 2 O = 1: 1, V / V),
(2) 0.1 mL test substance solution (5, 7.5% MCX liquid paraffin solution)
(3) A mixture of MCX liquid paraffin solution and FCA at twice the concentration of (2),
7 days later, after shaving the previous day, 0.2 mL of the test substance solution (5, 7.5% MCX liquid paraffin solution) was blocked for 48 hours at the injection site where a small amount of 10 W / V% sodium lauryl sulfate / white petrolatum had been applied. Apply and finish the sensitization procedure.
The induction test was carried out by applying 10 μl of the test solution (the test solution described in Table 2) to the shaved back and abdominal skin for 24 hours open 2 weeks after the end of the above operation.
For each test, the same number of animals that had been injected intradermally with only the FCA water emulsion were used as controls to distinguish nonspecific skin irritation reactions.
The determination was performed 48 hours after application according to the following determination criteria.
The sensitization rate and evaluation score were determined as follows.
Sensitization rate = number of animals exhibiting skin reaction / number of animals sensitized treatment = Σ (score for erythema + score for edema) / number of animals sensitized
[Table 2]
[0028]
Examples of the present invention will be given below.
In any case, the percutaneous absorption of the UV absorber is suppressed and has a stimulating and relaxing effect.
[0029]
Example 3 Sunscreen Octylmethoxycinnamate 7.5
DMPPG1000 2.0
t-Butylmethoxydibenzoylmethane 0.1
Titanium dioxide 5.0
Decamethylcyclopentasiloxane 30.0
POE / methylpolysiloxane copolymer 3.0
Organically modified montmorillonite 0.8
1,3-butylene glycol 5.0
Arbutin 5.0
Preservative Appropriate amount of perfume Appropriate amount of purified water Residue [0030]
Example 4 Cream
(Manufacturing method) The component A is heated and melted, and B is added with stirring. The mixture is processed with a homomixer to make the emulsified particles fine, and then rapidly cooled with stirring to obtain a cream.
[0031]
Example 5 Lotion
(Manufacturing method) B is adjusted. Separately, other components of A are dissolved in ethanol to prepare A, and this is added to B to solubilize, and filtered to obtain a lotion.
[0032]
Example 6 Latex
(Manufacturing method) B is adjusted and it maintains at 70 degreeC. The ingredients of A are mixed, heated and melted and kept at 70 ° C. A is added to B and uniformly emulsified with a homomixer and rapidly cooled with stirring to obtain an emulsion.
[0033]
Example 7 Sunscreen Hair Gel
(Manufacturing method) A is stirred and dissolved in B, and after adding C, it is dispersed with a disperser. D is added to this and stirred to obtain the desired hair gel.
[0034]
Example 8 Sunscreen Emulsification Foundation
(Manufacturing method) After stirring A, B sufficiently mixed and pulverized is added and homomixed. After dissolving C, it is added to this and subjected to a homomixer treatment to obtain a sunscreen emulsified foundation.
[0035]
【The invention's effect】
1) The external preparation for skin of the present invention is excellent in the effect of suppressing transdermal absorption of octyl methoxycinnamate , an ultraviolet absorber.
2) The external preparation for skin of the present invention is excellent in the skin irritation mitigating effect of octyl methoxycinnamate , an ultraviolet absorber.
3) The skin external preparation of this invention is excellent in the sensitization suppression effect of the ultraviolet absorber octyl methoxycinnamate .
4) The external preparation for skin according to the present invention is excellent in ultraviolet ray preventing effect and safety because octyl methoxycinnamate , an ultraviolet absorber, is not absorbed percutaneously.
[Brief description of the drawings]
FIG. 1 is a graph showing a 24-hour cumulative amount of octyl methoxycinnamate as an ultraviolet absorber.
FIG. 2 is a graph showing the results of a continuous skin irritation test of octylmethoxycinnamate as an ultraviolet absorber.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002003652A JP3683533B2 (en) | 2002-01-10 | 2002-01-10 | Topical skin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002003652A JP3683533B2 (en) | 2002-01-10 | 2002-01-10 | Topical skin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003206214A JP2003206214A (en) | 2003-07-22 |
JP3683533B2 true JP3683533B2 (en) | 2005-08-17 |
Family
ID=27643192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002003652A Expired - Lifetime JP3683533B2 (en) | 2002-01-10 | 2002-01-10 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3683533B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180054630A (en) | 2015-09-30 | 2018-05-24 | 가부시키가이샤 시세이도 | UV-blocking cosmetics |
WO2021125212A1 (en) | 2019-12-16 | 2021-06-24 | 株式会社 資生堂 | Sunscreen cosmetic |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015113297A (en) * | 2013-12-10 | 2015-06-22 | 花王株式会社 | Cosmetic composition |
WO2019151004A1 (en) * | 2018-01-30 | 2019-08-08 | 株式会社 資生堂 | Cosmetic material for sunscreen |
JP7188945B2 (en) * | 2018-01-30 | 2022-12-13 | 株式会社 資生堂 | sunscreen cosmetics |
-
2002
- 2002-01-10 JP JP2002003652A patent/JP3683533B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180054630A (en) | 2015-09-30 | 2018-05-24 | 가부시키가이샤 시세이도 | UV-blocking cosmetics |
US10328004B2 (en) | 2015-09-30 | 2019-06-25 | Shiseido Company, Ltd. | Sunscreen cosmetic |
WO2021125212A1 (en) | 2019-12-16 | 2021-06-24 | 株式会社 資生堂 | Sunscreen cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JP2003206214A (en) | 2003-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3763567B2 (en) | Cosmetics | |
JPH1053510A (en) | Composition for external use | |
CA3198046A1 (en) | Compositions and methods for deep dermal drug delivery | |
JPH04124122A (en) | Blackening agent of preventing gray hair | |
JP3614511B2 (en) | Oil-in-water emulsified cosmetic for sunscreen | |
TW200413017A (en) | External skin preparation | |
JP3683533B2 (en) | Topical skin preparation | |
JP2004002289A (en) | Parakeratosis inhibitor | |
KR101598623B1 (en) | UV blocking agents containing ethylhexyltriazone and the preparation method thereof, and the cosmetic composition containing the same | |
JP2004175750A (en) | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them | |
JP2006327965A (en) | Skin care preparation and application of the same | |
WO2001045697A1 (en) | Skin external agents and drugs | |
HU218946B (en) | Topical use of anorganic salts of stroncium (ii) for producing pharmaceutical compositions for treating eye pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JP4138679B2 (en) | Irritation relief agent | |
JP4053966B2 (en) | Skin external preparation and skin irritation relieving agent | |
JP2003335615A (en) | Water in oil type external preparation | |
JP4440556B2 (en) | Transdermal absorption enhancer and transdermal absorption preparation | |
JPH08337511A (en) | Melanin formation inhibitor | |
JPH1160494A (en) | Preparation for preventing recurrence of atopic dermatitis | |
JPH10114642A (en) | Skin preparation for external use | |
JP2006206491A (en) | Skin lotion | |
EP1919442B1 (en) | Non-tumorigenic ointment/cream base for topical application | |
JP2003183113A (en) | Composition for external use | |
JPH01261326A (en) | Skin cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040512 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050519 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3683533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090603 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100603 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100603 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110603 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110603 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120603 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130603 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |